675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)

• Yiran Zhang,
• Kelly Curtis,
• Lanjia Lin,
• John Park,
• Douglas Adkins,
• A Dimitrios Colevas,
• Natalie Rainey,
• Bruno Fang,
• Minh Phan,
• Katie Kerrigan,
• Venessa Chin,
• Diogo Alpuim Costa,
• José Dinis,
• Siu-Chi Chang Sun,
• Michael Howland

Affiliations

Yiran Zhang

10Gilead Sciences, Inc., Foster City, CA, USA

Kelly Curtis

10Gilead Sciences, Inc., Foster City, CA, USA

Lanjia Lin

13Gilead Sciences, Foster City, USA

John Park

Oxford Pleural Unit, Oxford Centre for Respiratory Medicine, Oxford University, Oxford, UK

Douglas Adkins

Washington University School of Medicine, St. Louis, MO, USA

A Dimitrios Colevas

1Stanford University, Stanford, CA, USA

Natalie Rainey

6Queensland Government – Cairns and Hinterland Hospital and Health Service, Queensland, QLD, Australia

Bruno Fang

7Astera Cancer Care, East Brunswick, NJ, USA

Minh Phan

5Sarah Cannon Research Institute at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Katie Kerrigan

2University of Utah, Salt Lake City, UT, USA

Venessa Chin

3Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Diogo Alpuim Costa

7Hospital CUF Descobertas, Lisboa, Portugal

José Dinis

8Portuguese Institute of Oncology (IPOPORTO), Porto North, Portugal

Siu-Chi Chang Sun

10Gilead Sciences, Inc., Foster City, CA, USA

Michael Howland

10Gilead Sciences, Inc., Foster City, CA, USA